Stock Price Quote

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE7639.4545.9 (+0.6 %)
PREV CLOSE ( ) 7593.55
OPEN PRICE ( ) 7641.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 351
TODAY'S LOW / HIGH ( )7523.75 7656.30
52 WK LOW / HIGH ( )4050.15 8139.85
NSE7611.8512.85 (+0.17 %)
PREV CLOSE( ) 7599.00
OPEN PRICE ( ) 7620.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 7611.85 (76)
VOLUME 5989
TODAY'S LOW / HIGH( ) 7499.85 7669.75
52 WK LOW / HIGH ( )4785 8139
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979
Management Info
Shilpa Divekar Nirula - Chairman Sanjeev Kumar Panchal - Managing Director
Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE

NEWS

12Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that, in accordance with the provi..
12Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that in accordance with the provis..
09Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that it enclosed certificate dated..
04Dec AstraZeneca Pharma India informs about
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
19Nov AstraZeneca Pharma to launch Breztri A
AstraZeneca Pharma India is all set to launch Budesonide Ph. Eur 160mcg+..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit384.3000000000011615.09
Gross Profit 510.300000000001 2195.37
Operating Profit 606.9000000000012192.52
Net Sales 408012955.28

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29796.40 (2.39%)
M.Cap ( in Cr)63315.27
Torrent Pharma (BSE)
peergroup  3259.40 (3.10%)
M.Cap ( in Cr)110312.91
Aarti Pharmalabs (BSE)
peergroup  740.55 (8.93%)
M.Cap ( in Cr)6711.31
Caplin Point Lab (BSE)
peergroup  2216.50 (2.11%)
M.Cap ( in Cr)16847.99
Procter&Gamble Healt (BSE)
peergroup  5448.00 (0.82%)
M.Cap ( in Cr)9043.34

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 5.04%
NON-INSTITUTION 16.87%
FI/BANKS/INSURANCE 0.13%
GOVERNMENT 0%
FII 0%

About Astrazeneca Pharma India Ltd.

Astrazeneca Pharma India Ltd. was incorporated in the year 1979. Its today's share price is 7639.45. Its current market capitalisation stands at Rs 19098.63 Cr. In the latest quarter, company has reported Gross Sales of Rs. 13021.4 Cr and Total Income of Rs.13303.3 Cr. The company's management includes Jesus Javier Diaz Ropero Esteso, Amita Bhave, Monica Widhani, Manasa R, Bhavana Agrawal, Sanjeev Kumar Panchal, Hooi-Bien Chuah, Sylvia Lorena Varela Ramon, Shilpa Divekar Nirula, Revathy Ashok.

It is listed on the BSE with a BSE Code of 506820 , NSE with an NSE Symbol of ASTRAZEN and ISIN of INE203A01020. It's Registered office is at Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring RoadBengaluru-560045, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AF Ferguson & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, Price Waterhouse & Co, Price Waterhouse & Co Chartered Accountants LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.